WO2021155871A1 - Suspensión oral con efecto antiulceroso y quimioprotector sobre el cáncer de colon y método para su preparación - Google Patents
Suspensión oral con efecto antiulceroso y quimioprotector sobre el cáncer de colon y método para su preparación Download PDFInfo
- Publication number
- WO2021155871A1 WO2021155871A1 PCT/CU2020/050008 CU2020050008W WO2021155871A1 WO 2021155871 A1 WO2021155871 A1 WO 2021155871A1 CU 2020050008 W CU2020050008 W CU 2020050008W WO 2021155871 A1 WO2021155871 A1 WO 2021155871A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- suspension
- extract
- microcrystalline cellulose
- rpm
- colon cancer
- Prior art date
Links
- 230000000767 anti-ulcer Effects 0.000 title claims abstract description 34
- 230000001767 chemoprotection Effects 0.000 title claims abstract description 22
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 19
- 208000029742 colonic neoplasm Diseases 0.000 title claims abstract description 19
- 229940100692 oral suspension Drugs 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 title description 5
- 239000000203 mixture Substances 0.000 claims abstract description 47
- 150000002191 fatty alcohols Chemical class 0.000 claims abstract description 41
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 33
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 33
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 33
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 235000013871 bee wax Nutrition 0.000 claims abstract description 14
- 239000012166 beeswax Substances 0.000 claims abstract description 14
- 230000008569 process Effects 0.000 claims abstract description 14
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 10
- 239000002245 particle Substances 0.000 claims abstract description 10
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 19
- 239000007900 aqueous suspension Substances 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 229920000136 polysorbate Polymers 0.000 claims description 5
- 229950008882 polysorbate Drugs 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 239000003765 sweetening agent Substances 0.000 claims description 4
- 241000256844 Apis mellifera Species 0.000 claims description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 3
- -1 polyoxyethylene Polymers 0.000 claims description 3
- 238000010008 shearing Methods 0.000 claims description 3
- 239000000375 suspending agent Substances 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 2
- 239000000341 volatile oil Substances 0.000 claims description 2
- 238000009736 wetting Methods 0.000 claims description 2
- 239000003906 humectant Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000001993 wax Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 abstract description 91
- 208000007107 Stomach Ulcer Diseases 0.000 abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 10
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- 230000000694 effects Effects 0.000 description 27
- 239000000126 substance Substances 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 26
- 238000011282 treatment Methods 0.000 description 24
- 241000700159 Rattus Species 0.000 description 22
- 208000025865 Ulcer Diseases 0.000 description 20
- 150000004667 medium chain fatty acids Chemical class 0.000 description 20
- 239000003826 tablet Substances 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 231100000397 ulcer Toxicity 0.000 description 18
- 201000005917 gastric ulcer Diseases 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 14
- 239000013641 positive control Substances 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 12
- DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical compound CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 10
- 230000002195 synergetic effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000013642 negative control Substances 0.000 description 9
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 8
- 229960000381 omeprazole Drugs 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 206010058314 Dysplasia Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000009826 neoplastic cell growth Effects 0.000 description 5
- 238000002627 tracheal intubation Methods 0.000 description 5
- 238000013019 agitation Methods 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 229920000084 Gum arabic Polymers 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000003699 antiulcer agent Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 239000003183 carcinogenic agent Substances 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 3
- 229960003132 halothane Drugs 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000013222 sprague-dawley male rat Methods 0.000 description 3
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- RHUYHJGZWVXEHW-UHFFFAOYSA-N 1,1-Dimethyhydrazine Chemical compound CN(C)N RHUYHJGZWVXEHW-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 238000012311 Shapiro-Wilk normality test Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000003568 Sodium, potassium and calcium salts of fatty acids Substances 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000001262 anti-secretory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000000079 gynecomastia Diseases 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000010951 particle size reduction Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000013966 potassium salts of fatty acid Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention reveals a new pharmaceutical composition consisting of an oral aqueous suspension for the prevention and treatment of gastric ulcers and colon cancer, as well as the process for preparing it.
- This suspension is characterized by containing a purified extract with the fatty alcohols of beeswax, microcrystalline cellulose and excipients accepted by the pharmaceutical industry.
- This invention is related to a new pharmaceutical composition, consisting of an oral aqueous suspension, as well as its method of obtaining it.
- Said suspension has antiulcer effects on the gastric mucosa and chemoprotective effects against colon cancer, and is characterized by containing, as active ingredients, a purified extract with fatty alcohols from refined beeswax Apis mellifera, which has been reduced by means of a technological procedure its particle size at ⁇ 1.5 microns, and microcrystalline cellulose.
- the purified extract of beeswax in addition to fatty alcohols, contains diols, paraffins and potassium salts of fatty acids as minor components.
- This new composition also presents a series of excipients accepted by the pharmaceutical industry, among these: one or more emulsifying agents, used in the step of reducing the particle size of the fatty alcohol extract, as well as wetting, sweetening, suspending, and preservative agents. , flavorings and water.
- one or more emulsifying agents used in the step of reducing the particle size of the fatty alcohol extract, as well as wetting, sweetening, suspending, and preservative agents. , flavorings and water.
- Gastric ulcer is a lesion that extends to the mucous layer and sometimes to the muscular layer of the stomach, forming a cavity with acute and chronic inflammation around it, this being the main cause of digestive bleeding, one of its main complications (Valle 2002, Sadic 2009). Other complications are perforation, penetration and obstruction, all of which lead to a significant impact on the patient's quality of life (Sung 2010).
- the ulcer is produced by an imbalance between aggressive factors (acid secretion, pepsin, H. pylori, non-steroidal anti-inflammatory) and defensive factors (mucus and bicarbonate secretion, blood microcirculation, prostaglandins, growth factors), being the infection by H.
- cancer is one of the main current causes of death, with more than 8 million deaths annually worldwide, with colon cancer being one of the five main causes of death worldwide with a trend increasing, especially in countries with fewer resources (Torre 2015, Chatenoud 2014).
- chemoprotective pharmaceutical compositions that can be used in the prevention and treatment of patients with this type of cancer or with risk factors for suffering it, such as ulcerative processes in the digestive tract (ulcerative colitis, Crohn's disease and others).
- the present invention reveals a new pharmaceutical composition consisting of an oral aqueous suspension for the prevention and treatment of gastric ulcers and colon cancer, as well as the process for preparing it.
- This suspension is characterized by containing a purified extract with the fatty alcohols of beeswax, microcrystalline cellulose and excipients accepted by the pharmaceutical industry.
- the method of preparing this suspension is characterized in that the fatty alcohol extract is subjected to a particle size reduction process to ⁇ 1.5 microns in the presence of an emulsifying agent at> 1000 rpm; the mixture of said active ingredient with microcrystalline cellulose in the proportion and concentration in which they are formulated, makes these components act synergistically, conferring powerful antiulcer and chemoprotective effects to this composition.
- this formulation has several drawbacks such as: a large size (655 mg) that leads to a high mass of excipients and high production costs; growing rejection in different countries of the use of two of its excipients (croscarmellose sodium and polyvinylpyrrolidone); and very low bioavailability of the fatty alcohols it contains ( ⁇ 10%).
- the pharmacological potency, as an antiulcer, of said tablet is much lower than the potency reached by the suspension object of the present invention.
- the fatty alcohol extract is subjected to technological processes of shearing or precipitation due to temperature change with stirring, in the presence of specific emulsifying agents, to reduce its particle size, and later be formulated in an aqueous suspension, mixed with microcrystalline cellulose in specific proportions and concentrations, its pharmacological efficacy is synergistically enhanced, which was not deductible from the state of the art.
- the aqueous suspension object of this invention significantly exceeds the antiulcer effect, both of the fatty alcohol extract in the form of tablets, and of the microcrystalline cellulose, and presents a powerful chemoprotective effect on colon cancer that had not been previously reported for either of these two substances, which can be seen in the examples of realization.
- microcrystalline cellulose (derived from alphacellulose) has been used mainly in the manufacture of creams and solid suspensions for cosmetics, detergents and as a stabilizer in food (Nsor-Atindana, 2017).
- it is used for the preparation of tablets and capsules, as a compression and filling agent, although its bile acid sequestering capacity has also been reported (Paniagua 1999) and it has been used as an active ingredient in a suspension with antiulcer effect. at a dose of 12% (Barzaga 2004).
- the procedure for obtaining the pharmaceutical composition object of the present invention is characterized by: A) mixing an extract of fatty alcohols extracted from beeswax (1-2%), with polyoxyethylene hydrogenated castor oil or polysorbate (2-4%), substances used as emulsifying agents; B) subjecting said mixture to a technological process to reduce the particle size of the extract to ⁇ 1.5 microns, which can be done with a homogenizing equipment capable of shearing the particles at> 1000 rpm and> 80 ° C for> 1 minute , or subjecting said mixture to a stirring speed> 1000 rpm and> 80 ° C for> 1 minute and then reducing the temperature to ⁇ 60 ° C with the same stirring speed; C) keeping stirring, incorporate microcrystalline cellulose as second active ingredient (1-2%), methyl and propyl parabens as preservatives (0.1-0.6%), glycerin as wetting agent (20-30 %), sorbitol or sodium saccharin as sweetening agents (1-6%), carboxymethylcellulose as
- This new pharmaceutical composition is intended to prevent or treat ulcerative processes and other related conditions, given its protective nature on the digestive tract, and its chemoprotective effects on colon cancer.
- the proportion in which the active ingredients are present in this pharmaceutical composition is the result of several studies carried out with a view to standardizing the contents of both active ingredients and excipients in the final composition at specific concentrations and proportions that guarantee the desired pharmacological effects. which are the result of a synergistic action of the active ingredients it contains.
- potent pharmacological effects of the present composition are far superior to those of effects of separately administering both active ingredients, even at doses higher than the doses in which they are present in the present composition, which can be appreciated in the Exemplary Executives and demonstrates the occurrence of a non-deductible synergistic effect of the state of the art.
- composition obtained in example 1 was subjected to a preclinical test with animals, in which its antiulcer effect was compared with the antiulcer effects of the registered fatty alcohol tablet (TAR), and of alcohol suspensions Fatty (FA) and microcrystalline cellulose (CM), respectively, the latter two prepared with doses of FA and CM equal to the doses of both substances in AGCM suspension.
- the experimental model used in this trial was the induction of gastric ulcers in rats by sodium hydroxide.
- mice Male Sprague-Dawley rats (250-300 g) were used which were adapted for 7 days to the usual laboratory conditions at 20-250C, relative humidity of 60 ⁇ 5%, light / dark cycles of 12 hours. and with free access to water and I think standard for rodents. After completing the quarantine, the animals were randomly distributed into 10 experimental groups (10 rats / group): a negative control that only received the vehicle and 9 groups that were induced to ulcer with 0.2 N sodium hydroxide, between These were a positive control not treated with any antiulcer agent and 8 groups treated with the substances to be evaluated as shown in table 1. The suspensions were administered as is, while the ART was prepared in acacia gum / water vehicle (1%) .
- Lesion score was defined as the sum total of lesion size in mm2 (Ohara 1992).
- CM Microcrystalline cellulose suspension AG: Fatty alcohol suspension
- TAR Fatty alcohol tablet registered as nutritional supplement I inhibition, Data as Mean ⁇ SEM (standard error of the mean)
- the MCFA suspension (25 and 200 mg / kg) produced a reduction in the ulcer index, which was significant not only compared to the positive control, but also with respect to the same doses of the MC, AG and ART suspensions. Therefore, the highest anti-ulcer efficacy was achieved with the MCFA suspension, especially since it produced a ⁇ 100% inhibition, that is, total, of the gastric ulcer index with the highest dose tested of 200 mg / kg.
- the AGCM suspension produced percentages of inhibition higher than the sum of those achieved with the CM and AG suspensions separately, showing a synergism of the AGCM, where the presence of the AG extract and the CM in the proportions and concentrations in which they appear promotes the greatest anti-ulcer efficacy.
- the lowest dose tested of 25 mg / kg of the MCFA suspension produced a high percentage of inhibition of 86.5% on gastric ulcers, which indicates that in addition to a high efficiency, the AGCM suspension also has high power.
- Example 2 The composition obtained in Example 2 (MCFA) was subjected to a preclinical test with animals, in which its antiulcer effect was compared with the antiulcer effects of the registered fatty alcohol tablet (TAR), and alcohol suspensions Fatty (AG) and microcrystalline cellulose (CM), the latter two prepared with doses of AG and CM equal to the doses of both substances in the AGCM suspension.
- the experimental model used in this trial was the induction of gastric ulcers in rats by ethanol.
- mice Male Sprague-Dawley rats (250-300 g) were used which were adapted for 7 days to the usual laboratory conditions at 20-250C, relative humidity of 60 ⁇ 5%, light / dark cycles of 12 hours. and with free access to water and I think standard for rodents. After completing the quarantine, the animals were randomly distributed into 11 experimental groups (10 rats / group): a negative control that only received the vehicle and 10 groups in which the ulcer was induced with 60% ethanol, among these a control positive not treated with any antiulcer agent, 8 groups treated with the substances to be evaluated and one group treated with Omeprazole as a reference substance, as shown in Table 2.
- 11 experimental groups (10 rats / group): a negative control that only received the vehicle and 10 groups in which the ulcer was induced with 60% ethanol, among these a control positive not treated with any antiulcer agent, 8 groups treated with the substances to be evaluated and one group treated with Omeprazole as a reference substance, as shown in Table 2.
- the suspensions were administered as is, while to administer the tablet a suspension with 1% acacia gum was prepared.
- a negative control group not subjected to damage with ethanol
- a positive control subjected to damage and without treatment with any substance
- All treatments and ethanol were administered orally, as a single dose, by intragastric intubation.
- the selected doses are within the range of effective doses verified in previous preliminary experiments and the dose of omeprazole (20 mg / kg) has also been effective in this model.
- the animals were subjected to a 24-hour fast prior to the experiment, with free access to water.
- each rat received the ulcer-inducing agent (1 mL / 200 g) by gastric intubation.
- the rats were sacrificed in a halothane atmosphere, the stomachs were removed and opened by the greater curvature.
- the quantification of the gastric ulcer index was carried out as described in example 3.
- TAR Fatty alcohol tablet registered as nutritional supplement I inhibition, Data as Mean ⁇ SEM (standard error of the mean)
- composition obtained in example 2 was subjected to a preclinical test with animals, in which its antiulcer effect was compared with the antiulcer effects of the registered fatty alcohol tablet (TAR), and alcohol suspensions Fatty (AG) and microcrystalline cellulose (CM), the latter two prepared with doses of AG and CM equal to the doses of both substances in the AGCM suspension.
- the experimental model used in this trial was the induction of gastric ulcers in rats by pyloric ligation, which is a model acid dependent, unlike the model presented in the previous example.
- mice Male Sprague-Dawley rats (250-300 g) were used, which were adapted for 7 days to the usual laboratory conditions at 20-250C, relative humidity of 60 ⁇ 5%, light / dark cycles of 12 hours and with free access to water and standard feed for rodents. After completing the quarantine, the animals were randomly distributed into 11 experimental groups (10 rats / group): a negative control that only received the vehicle and 10 groups that were induced to ulcer by pyloric ligation, including a positive control. not treated with any antiulcer agent, 8 groups treated with the substances to be evaluated and one group treated with Omeprazole as a reference substance, as shown in Table 3.
- the suspensions were administered as is, while a suspension was prepared to administer the tablet with 1% acacia gum.
- a negative control group not subjected to pyloric ligation
- a positive control subjected to damage and without treatment with any substance
- All treatments were administered orally, as a single dose, by intragastric intubation.
- the selected doses are within the range of effective doses verified in previous preliminary experiments and the dose of omeprazole (20 mg / kg) has also been effective in this model.
- the animals were subjected to a 24-hour fast prior to the experiment, with free access to water.
- the AGCM suspension is the substance evaluated that has the highest anti-ulcer efficacy, since it was significantly superior to ART, and to suspensions with the respective monotherapies of GA and CM, respectively. Furthermore, the fact that the inhibition achieved by the AGCM suspension was greater than the sum of those achieved individually with CM and AG, demonstrates the synergistic effect of the presence of these two components in the AGCM suspension mixture.
- MCFA Suspension of fatty alcohols plus microcrystalline cellulose
- CM Microcrystalline cellulose suspension AG: Fatty alcohol suspension
- TAR Fatty alcohol tablet registered as nutritional supplement I inhibition, Data as Mean ⁇ SEM (standard error of the mean)
- Example 1 The composition obtained in Example 1 (MCFA) was subjected to a preclinical test with animals, in which its chemoprotective effect was compared with the chemoprotective effects of the registered fatty alcohol tablet (TAR), and of alcohol suspensions Fatty (AG) and microcrystalline cellulose (CM), the latter two prepared with doses of AG and CM equal to the doses of both substances in the AGCM suspension.
- TAR registered fatty alcohol tablet
- CM microcrystalline cellulose
- colon cancer was induced in 45 Holtzmann rats with 1,2-dimethylhydrazine (DMH).
- the animals three months old and 250 ⁇ 20 g; they were randomly distributed into the following groups: sodium polysorbate at 2 mL / kg; DMH 20 mg / kg; DMH plus AGCM suspension; DMH plus suspension AG; DMH plus CM suspension.
- DMH was prepared at 4 mg / mL in distilled water, with 0.4 mg / mL of EDTA as a stabilizer at pH 6.5. 20 mg / kg of body weight was administered subcutaneously once a week for 18 weeks and the suspensions and polysorbate were administered orally for the 18 weeks that the study lasted. After the expected time, one hour after the last administration, the rats were sacrificed with pentobarbital 100 mg / kg, and the colon was extracted for the histopathological analysis, it was gently washed with saline solution to remove the blood and adhered debris.
- the areas of tumor mass were fixed in 10% formaldehyde solution, buffered for 7 days; then, parts of 3-5 um were selected and fixed in paraffin, later they were stained with hematoxylin and eosin.
- the evaluation was based on microscopic observations: neoplasia and dysplasia.
- the statistical analysis to evaluate the chemoprotective effect was the Shapiro-Wilk normality test and, later, the Krustal Wallis non-parametric test with a 95% confidence level.
- Table 4 summarizes the percentage of histopathological observations of the colon of rats induced with colon cancer by DMH and that received the different suspensions.
- PS 3% sodium polysorbate.
- This invention has industrial application, the composition is novel, and both the suspension itself and its production process are inventive, as it is not deductible from the state of the art that the mixture of two different antiulcer active ingredients, in proportions and Specific concentrations, none of which have a demonstrated chemoprotective effect on carcinogenic processes, show a synergistic effect with pharmacological benefits on gastric ulcers and a chemoprotective effect on colon cancer.
- the present invention is related to the food and pharmaceutical industries, since the composition obtained can be used as a nutritional supplement, due to its beneficial preventive effects on the digestive tract, and also as a medicine for the treatment of ulcers and cancer.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Insects & Arthropods (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2020427452A AU2020427452B2 (en) | 2020-02-03 | 2020-12-14 | Oral suspension with anti-ulcerous and chemoprotective effect on colon cancer and preparation method thereof |
CA3169969A CA3169969A1 (en) | 2020-02-03 | 2020-12-14 | Oral suspension with antiulcerous and chemoprotective effect on colon cancer and method for its preparation |
EP20917601.5A EP4101444A4 (en) | 2020-02-03 | 2020-12-14 | ORAL SUSPENSION WITH ANTI-ULCEROUS AND CHEOPROTECTIVE EFFECT ON COLON CANCER AND METHOD FOR ITS PREPARATION |
CN202080095526.6A CN115087432A (zh) | 2020-02-03 | 2020-12-14 | 具有抗溃疡和对结肠癌的化学保护性作用的口服悬浮液及其制备方法 |
KR1020227030797A KR20230129150A (ko) | 2020-02-03 | 2020-12-14 | 결장암에 대한 항궤양 및 화학보호 효과를 갖는 경구 현탁액 및 그의 제조 방법 |
JP2022547267A JP2023518659A (ja) | 2020-02-03 | 2020-12-14 | 結腸癌に対する抗潰瘍性及び化学的防御効果を有する経口懸濁液及びその調製方法 |
US17/797,022 US20230071637A1 (en) | 2020-02-03 | 2020-12-14 | Oral suspension with antiulcerous and chemoprotective effect on colon cancer and preparation method thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2020-0007 | 2020-02-03 | ||
CU2020000007A CU24638B1 (es) | 2020-02-03 | 2020-02-03 | Suspensión oral con efecto antiulceroso y quimioprotector sobre el cáncer de colon |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021155871A1 true WO2021155871A1 (es) | 2021-08-12 |
Family
ID=77199690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2020/050008 WO2021155871A1 (es) | 2020-02-03 | 2020-12-14 | Suspensión oral con efecto antiulceroso y quimioprotector sobre el cáncer de colon y método para su preparación |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230071637A1 (es) |
EP (1) | EP4101444A4 (es) |
JP (1) | JP2023518659A (es) |
KR (1) | KR20230129150A (es) |
CN (1) | CN115087432A (es) |
AU (1) | AU2020427452B2 (es) |
CA (1) | CA3169969A1 (es) |
CU (1) | CU24638B1 (es) |
WO (1) | WO2021155871A1 (es) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994007830A1 (en) * | 1992-09-29 | 1994-04-14 | Laboratorios Dalmer Sa | A mixture of higher primary aliphatic alcohols, its obtention from sugar cane wax and its pharmaceutical uses |
CU22412A1 (es) | 1993-11-09 | 1996-01-31 | Dalmer Lab Sa | Una mezcla natural compuesta por alcoholes alifaticos primarios superiores obtenidos de la cera de abejas para el tratamiento de las ulceras gastricas y duodenales que presenta tambien actividad antiinflamatoria |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1125096A (zh) * | 1994-12-23 | 1996-06-26 | 戴默实验室股份公司 | 由来自蜂蜡的高级脂肪伯醇组成的天然混合物 |
CU22723A1 (es) * | 1997-04-02 | 2002-02-28 | Dalmer Lab Sa | Mezcla de ácidos grasos primarios de alto peso molecular obtenidos de la cera de cana de azúcar y sus usos farmacéuticos |
-
2020
- 2020-02-03 CU CU2020000007A patent/CU24638B1/es unknown
- 2020-12-14 CA CA3169969A patent/CA3169969A1/en active Pending
- 2020-12-14 EP EP20917601.5A patent/EP4101444A4/en active Pending
- 2020-12-14 US US17/797,022 patent/US20230071637A1/en active Pending
- 2020-12-14 JP JP2022547267A patent/JP2023518659A/ja active Pending
- 2020-12-14 AU AU2020427452A patent/AU2020427452B2/en active Active
- 2020-12-14 CN CN202080095526.6A patent/CN115087432A/zh active Pending
- 2020-12-14 WO PCT/CU2020/050008 patent/WO2021155871A1/es active Application Filing
- 2020-12-14 KR KR1020227030797A patent/KR20230129150A/ko unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994007830A1 (en) * | 1992-09-29 | 1994-04-14 | Laboratorios Dalmer Sa | A mixture of higher primary aliphatic alcohols, its obtention from sugar cane wax and its pharmaceutical uses |
CU22412A1 (es) | 1993-11-09 | 1996-01-31 | Dalmer Lab Sa | Una mezcla natural compuesta por alcoholes alifaticos primarios superiores obtenidos de la cera de abejas para el tratamiento de las ulceras gastricas y duodenales que presenta tambien actividad antiinflamatoria |
Non-Patent Citations (2)
Title |
---|
BARGAZA PEDRO GILBERTO ET AL.: "Actividad antiulcerosa y toxicidad aguda oral de celulosa microcristalina al 12%", REVISTA CUBA NA DE FARMACIA, vol. 38, no. 2, 2004, XP055847625, Retrieved from the Internet <URL:http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75152004000200005> [retrieved on 20210527] * |
See also references of EP4101444A4 |
Also Published As
Publication number | Publication date |
---|---|
CN115087432A (zh) | 2022-09-20 |
EP4101444A1 (en) | 2022-12-14 |
CU20200007A7 (es) | 2021-09-07 |
CA3169969A1 (en) | 2021-08-12 |
JP2023518659A (ja) | 2023-05-08 |
AU2020427452A1 (en) | 2022-09-22 |
EP4101444A4 (en) | 2024-02-28 |
AU2020427452B2 (en) | 2023-11-23 |
CU24638B1 (es) | 2023-01-16 |
KR20230129150A (ko) | 2023-09-06 |
US20230071637A1 (en) | 2023-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Goyal et al. | Asparagus racemosus-an update | |
EP2026763B1 (en) | A method to reduce the symptoms of heartburn and gastro-oesophageal reflux disease (gerd) by specific polysaccharides | |
KR100439323B1 (ko) | 비막에 아연을 송달하기 위한 방법 및 조성물 | |
KR20040020056A (ko) | 위식도 역류 질환 및 야간 위산분비의 치료 방법 | |
WO2008031322A1 (fr) | Application d'un médicament inhibiteur d'acétylcholine estérase à base d'un extrait de leonurus utilisé en tant que cholinomimétique | |
CN112915113B (zh) | 鸦胆子油乳剂在制备治疗或预防口腔溃疡的药物中的用途 | |
WO2021155871A1 (es) | Suspensión oral con efecto antiulceroso y quimioprotector sobre el cáncer de colon y método para su preparación | |
CN104144680A (zh) | 含有来自北美鹅掌楸树皮的提取物作为活性成分的改善剂型 | |
JP2006512354A (ja) | 抗潰瘍薬草配合物 | |
TW201904606A (zh) | 小麥肽和岩藻多糖的組合物、其製備和使用方法 | |
CN107174662A (zh) | 质子泵抑制剂和胃粘膜保护剂组成的复合物及其用途 | |
WO2005049053A1 (en) | Composition comprising a magnesium compound and/or a magnesium saltfor improving sexual dysfunction | |
JP5303093B2 (ja) | テナトプラゾール及びヒスタミンh2受容体拮抗剤を組み合わせた医薬組成物 | |
CN111920908A (zh) | 一种治疗消化性溃疡的药物组合物 | |
ES2603782T3 (es) | El uso de una parte de superficie de Hedychium Coronarium Koenig en la reducción de la glucosa en sangre; extractos y composiciones de partes enterradas de Hedychium Coronarium Koenig y sus usos | |
RU2806636C1 (ru) | Суспензия для приема внутрь с противоязвенным и химиопротективным действием при раке толстой кишки и способ ее приготовления | |
JP2001509791A (ja) | 胃腸障害の治療用組成物及び方法 | |
CN112933091B (zh) | 一种抗胃酸类疾病的药物组合物及应用 | |
US11723939B2 (en) | Composition for gastric and oesophageal diseases | |
ES2316368T3 (es) | Lactoalbumina para el tratamiento curativo de ulceras peptidicas. | |
CN113171372A (zh) | 一种胃滞留剂、其制备方法及用途 | |
RU2185183C1 (ru) | Способ лечения язвенно-эрозивных поражений гастродуоденальной зоны | |
JP2001501224A (ja) | 胸焼けを予防及び治療するための方法及び組成物 | |
CN105343823A (zh) | 一种治疗消化性溃疡的水提物颗粒剂 | |
JPH0832630B2 (ja) | 胃腸病の治療用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20917601 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022547267 Country of ref document: JP Kind code of ref document: A Ref document number: 3169969 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2020427452 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020917601 Country of ref document: EP Effective date: 20220905 |
|
ENP | Entry into the national phase |
Ref document number: 2020427452 Country of ref document: AU Date of ref document: 20201214 Kind code of ref document: A |